Vaxart, Inc. (VXRT) Free cash flow
- Free cash flow · 12 months (USD): Value $33.38M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value 13.73%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $33.38M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $33.98M − $601.00K ≈ $33.38M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 13.73% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $33.38M ÷ $243.06M × 100 ≈ 13.73% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $33.98M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.53× | Operating cash flow / net income. Period ending 2026-06-30. $33.98M ÷ $22.28M ≈ 1.53× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 33.98M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 601.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 33.38M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 243.06M USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 22.28M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $33.38M | (m) | $33.98M | $601.00K | (m) | $243.06M | (m) | $22.28M | (m) | (m) | 13.73% | 1.53× |
| 2026-03-31 | $14.80M | (m) | $15.26M | $463.00K | (m) | $255.61M | (m) | $37.10M | (m) | (m) | 5.79% | 0.41× |
| 2025-12-31 | $7.57M | (m) | $7.71M | $145.00K | (m) | $237.26M | (m) | $16.33M | (m) | (m) | 3.19% | 0.47× |
| 2025-09-30 | $-30.48M | (m) | $-30.29M | $188.00K | (m) | $148.20M | (m) | $-50.70M | (m) | (m) | -20.57% | 0.60× |
| 2025-06-30 | $-37.17M | (m) | $-37.09M | $80.00K | (m) | $80.72M | (m) | $-56.64M | (m) | (m) | -46.05% | 0.65× |
| 2025-03-31 | $-33.73M | (m) | $-33.17M | $553.00K | (m) | $47.40M | (m) | $-58.12M | (m) | (m) | -71.16% | 0.57× |
| 2024-12-31 | $-45.32M | (m) | $-44.76M | $554.00K | (m) | $28.70M | (m) | $-66.95M | (m) | (m) | -157.90% | 0.67× |
| 2024-09-30 | $-51.35M | (m) | $-50.94M | $406.00K | (m) | (m) | (m) | $-72.34M | (m) | (m) | (m) | 0.70× |
| 2024-06-30 | $-62.42M | (m) | $-61.74M | $679.00K | (m) | (m) | (m) | $-75.66M | (m) | (m) | (m) | 0.82× |
| 2024-03-31 | $-67.95M | (m) | $-67.18M | $763.00K | (m) | (m) | (m) | $-81.74M | (m) | (m) | (m) | 0.82× |
| 2023-12-31 | $-72.32M | (m) | $-70.45M | $1.87M | (m) | (m) | (m) | $-82.47M | (m) | (m) | (m) | 0.85× |
| 2023-09-30 | $-91.96M | (m) | $-86.08M | $5.88M | (m) | (m) | (m) | $-89.01M | (m) | (m) | (m) | 0.97× |
| 2023-06-30 | $-93.32M | (m) | $-85.70M | $7.62M | (m) | (m) | (m) | $-100.92M | (m) | (m) | (m) | 0.85× |
| 2023-03-31 | $-103.62M | (m) | $-94.13M | $9.49M | (m) | (m) | (m) | $-107.80M | (m) | (m) | (m) | 0.87× |
| 2022-12-31 | $-104.38M | (m) | $-94.78M | $9.60M | (m) | (m) | (m) | $-107.76M | (m) | (m) | (m) | 0.88× |
| 2022-09-30 | $-88.16M | (m) | $-81.44M | $6.71M | (m) | (m) | (m) | $-104.60M | (m) | (m) | (m) | 0.78× |
| 2022-06-30 | $-87.10M | (m) | $-81.09M | $6.01M | (m) | (m) | (m) | $-92.88M | (m) | (m) | (m) | 0.87× |
| 2022-03-31 | $-74.24M | (m) | $-68.35M | $5.89M | (m) | (m) | (m) | $-79.56M | (m) | (m) | (m) | 0.86× |
| 2021-12-31 | $-64.99M | (m) | $-59.83M | $5.16M | (m) | (m) | (m) | $-70.47M | (m) | (m) | (m) | 0.85× |
| 2021-09-30 | $-59.83M | (m) | $-54.78M | $5.04M | (m) | (m) | (m) | $-63.57M | (m) | (m) | (m) | 0.86× |
| 2021-06-30 | $-53.80M | (m) | $-49.77M | $4.03M | (m) | (m) | (m) | $-54.07M | (m) | (m) | (m) | 0.92× |
| 2021-03-31 | $-38.97M | (m) | $-37.13M | $1.83M | (m) | (m) | (m) | $-46.93M | (m) | (m) | (m) | 0.79× |
| 2020-12-31 | $-24.97M | (m) | $-23.75M | $1.22M | (m) | (m) | (m) | $-32.22M | (m) | (m) | (m) | 0.74× |
| 2020-09-30 | $-17.11M | (m) | $-16.78M | $333.00K | (m) | (m) | (m) | $-24.77M | (m) | (m) | (m) | 0.68× |
| 2020-06-30 | $-12.00M | (m) | $-11.85M | $152.00K | (m) | (m) | (m) | $-21.94M | (m) | (m) | (m) | 0.54× |
| 2020-03-31 | $-11.95M | (m) | $-11.64M | $302.00K | (m) | (m) | (m) | $-18.60M | (m) | (m) | (m) | 0.63× |
| 2019-12-31 | $-13.94M | (m) | $-13.09M | $850.00K | (m) | (m) | (m) | $-18.64M | (m) | (m) | (m) | 0.70× |
| 2019-09-30 | $-16.03M | (m) | $-15.00M | $1.03M | (m) | (m) | (m) | $-17.14M | (m) | (m) | (m) | 0.88× |
| 2019-06-30 | $-17.11M | (m) | $-16.03M | $1.08M | (m) | (m) | (m) | $-18.43M | (m) | (m) | (m) | 0.87× |
| 2019-03-31 | $-9.73M | (m) | $-8.61M | $1.12M | (m) | $8.06M | (m) | $-21.66M | (m) | (m) | -120.67% | 0.40× |
| 2018-12-31 | $-15.26M | (m) | $-14.55M | $707.00K | (m) | $4.16M | (m) | $-18.01M | (m) | (m) | -366.79% | 0.81× |
| 2018-09-30 | (m) | (m) | $-13.55M | (m) | (m) | $5.09M | (m) | $-16.50M | (m) | (m) | (m) | 0.82× |
| 2018-06-30 | (m) | (m) | $-12.69M | (m) | (m) | $4.91M | (m) | $-15.26M | (m) | (m) | (m) | 0.83× |
| 2018-03-31 | (m) | (m) | $-18.59M | (m) | (m) | $4.40M | (m) | $-12.29M | (m) | (m) | (m) | 1.51× |
| 2017-12-31 | (m) | (m) | $-19.50M | (m) | (m) | $7.80M | (m) | $-19.00M | (m) | (m) | (m) | 1.03× |
| 2017-09-30 | (m) | (m) | $-23.80M | (m) | (m) | $8.90M | (m) | $-24.70M | (m) | (m) | (m) | 0.96× |
| 2017-06-30 | (m) | (m) | $-30.00M | (m) | (m) | $8.90M | (m) | $-29.40M | (m) | (m) | (m) | 1.02× |
| 2017-03-31 | (m) | (m) | $-30.10M | (m) | (m) | $9.30M | (m) | $-30.50M | (m) | (m) | (m) | 0.99× |
| 2016-12-31 | (m) | (m) | $-25.60M | (m) | (m) | $9.80M | (m) | $-31.30M | (m) | (m) | (m) | 0.82× |
| 2016-09-30 | (m) | (m) | $-25.70M | (m) | (m) | $7.70M | (m) | $-28.80M | (m) | (m) | (m) | 0.89× |
| 2016-06-30 | $-14.30M | (m) | $-14.10M | $200.00K | (m) | $9.30M | (m) | $-25.40M | (m) | (m) | -153.76% | 0.56× |
| 2016-03-31 | $-15.10M | (m) | $-15.00M | $100.00K | (m) | $12.90M | (m) | $-38.30M | (m) | (m) | -117.05% | 0.39× |
| 2015-12-31 | (m) | (m) | $-7.20M | (m) | (m) | $13.40M | (m) | $-31.90M | (m) | (m) | (m) | 0.23× |
| 2015-09-30 | (m) | (m) | $2.90M | (m) | (m) | $25.60M | (m) | $-18.80M | (m) | (m) | (m) | -0.15× |
| 2015-06-30 | $-9.70M | (m) | $-9.60M | $100.00K | (m) | $24.60M | (m) | $-19.10M | (m) | (m) | -39.43% | 0.50× |
| 2015-03-31 | $800.00K | (m) | $800.00K | $0.00 | (m) | $28.90M | (m) | $-9.40M | (m) | (m) | 2.77% | -0.09× |
| 2014-12-31 | (m) | (m) | $700.00K | (m) | (m) | $52.50M | (m) | $-7.40M | (m) | (m) | (m) | -0.09× |
| 2014-09-30 | (m) | (m) | $-8.70M | (m) | (m) | $57.10M | (m) | $-14.00M | (m) | (m) | (m) | 0.62× |
| 2014-06-30 | $-3.40M | (m) | $-3.30M | $100.00K | (m) | $68.70M | (m) | $-11.00M | (m) | (m) | -4.95% | 0.30× |
| 2014-03-31 | $-12.10M | (m) | $-11.40M | $700.00K | (m) | $69.60M | (m) | $-7.10M | (m) | (m) | -17.39% | 1.61× |
| 2013-12-31 | $-16.40M | (m) | $-15.70M | $700.00K | (m) | $52.60M | (m) | $-10.10M | (m) | (m) | -31.18% | 1.55× |
| 2013-09-30 | $-15.80M | (m) | $-14.90M | $900.00K | (m) | $44.40M | (m) | $-5.40M | (m) | (m) | -35.59% | 2.76× |
| 2013-06-30 | $-14.90M | (m) | $-13.90M | $1.00M | (m) | $33.60M | (m) | $-8.70M | (m) | (m) | -44.35% | 1.60× |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | $24.14M | (m) | $-1.78M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | $12.28M | (m) | $-2.43M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | $-6.29M | (m) | (m) | $2.73M | (m) | $-9.25M | (m) | (m) | (m) | 0.68× |
| 2012-06-30 | (m) | (m) | $-9.88M | (m) | (m) | $3.18M | (m) | $-5.08M | (m) | (m) | (m) | 1.94× |
| 2012-03-31 | (m) | (m) | $-8.08M | (m) | (m) | $6.30M | (m) | $-6.95M | (m) | (m) | (m) | 1.16× |
| 2011-12-31 | $-15.17M | (m) | $-15.17M | $1.00K | (m) | $14.84M | (m) | $-4.53M | (m) | (m) | -102.22% | 3.35× |
| 2011-09-24 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $-34.40M | (m) | $-33.70M | $700.00K | (m) | $12.50M | (m) | $-25.40M | (m) | (m) | -275.20% | 1.33× |
| 2011-06-25 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-26 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-25 | $39.78M | (m) | $39.93M | $154.00K | (m) | $35.01M | (m) | $878.00K | (m) | (m) | 113.64% | 45.48× |
| 2010-09-25 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-26 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-26 | $6.21M | (m) | $6.22M | $4.00K | (m) | $10.49M | (m) | $-18.73M | (m) | (m) | 59.23% | -0.33× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |